pharmaceuticals

Hyperion acquires Andromeda for up to $570m

The Clal Biotechnology subsidiary has an immune intervention therapy for Type 1 diabetes in a Phase III clinical trial.

BusinessWire
Twitter Facebook Linkedin RSS Newsletters